Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare the results of intravitreal bevacizumab (IVB) injection alone or in combination with intravitreal 1 mg triamcinolone acetonide (IVT) in center-involved diabetic macular edema.

Methods

In this randomized clinical trial study, ninety-two eyes of 46 patients with bilateral center-involved diabetic macular edema and no previous treatment were included in the study. One eye of each patient was randomly assigned to 1.25 mg of IVB injection or combination of 1.25 IVB and 1 mg IVT. Evaluation of best-corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP) and grading of lens opacity was conducted at baseline, and weeks 2, 4, 6, 8, 12 and 24 after treatment. Retreatment was performed at a 6-week interval whenever indicated based on CMT.

Results

Between the groups, BCVA changes were not statistically different until 24-week follow-up (P > 0.05), but at 24 weeks after treatment, BCVA improvement was significantly better in IVB group (P = 0.049). Significant CMT reduction was observed in each group along the follow-up period (P = 0.001). The mean CMT reduction was more significant in combination (IVB + IVT) group at 2 weeks of follow-up (P < 0.001), but CMT changes were not significant between the groups at weeks 12th and 24th after injection. Overall, retreatment was applied for 59 eyes up to 24 weeks (33 in the IVB group, 26 in the IVB + IVT group). Among patients with 2 or more injections, number of injections was significantly lower in IVB + IVT group (P = 0.043). Three eyes within IVB + IVT group developed IOP rise beyond 21 mmHg, which were controlled with topical anti-glaucoma medications within 1 week. Changes in lens opacity were not significant between two groups.

Conclusion

Eyes treated with IVB plus 1 mg IVT injections had more significant reduction in CMT in early post-injection, but this effect was transient. Although after 24 weeks visual acuity improvement was better in IVB group, combination therapy may decrease the number of injections. Combining 1 mg of intravitreal triamcinolone with bevacizumab was not accompanied with significant side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Munoz B, West SK, Rubin GS et al (2000) Causes of blindness and visual impairment in a population of older Americans: the Salisbury Eye Evaluation Study. Arch Ophthalmol 118:819–825

    Article  CAS  PubMed  Google Scholar 

  2. Moss SE, Klein R, Klein BE (1998) The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105:998–1003

    Article  CAS  PubMed  Google Scholar 

  3. Yau JW, Sl Rogers, Kawasaki R et al (2012) Meta-analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:556–564

    Article  PubMed  PubMed Central  Google Scholar 

  4. Klein BEK, Myers CE, Howard KP, Klein R (2015) Serum lipids and proliferative diabetic retinopathy and macular edema in persons with long term type 1 diabetes: the Wisconsin epidemiologic study of diabetic retinopathy. JAMA Ophthalmol 133(5):503–510

    Article  PubMed  PubMed Central  Google Scholar 

  5. Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103:1796–1805

    Article  Google Scholar 

  6. Early Treatment Diabetic Retinopathy Study Research Group (1995) Focal photocoagulation treatment of diabetic macular edema: relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Arch Ophthalmol 113:1144–1155

    Article  Google Scholar 

  7. Tranos PG, Wickremasinghe SS, Stangos NT et al (2004) Macular edema. Surv Ophthalmol 49:470–490

    Article  PubMed  Google Scholar 

  8. Arnarsson A, Stefansson E (2000) Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 41(3):877–879

    CAS  PubMed  Google Scholar 

  9. Chun DW, Heier JS, Topping TM et al (2006) A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113:1706–1712

    Article  PubMed  Google Scholar 

  10. Rakhee A, Ajay A, Sagdeo M (2014) Effect of combined intravitreal injections of bevacizumab and triamcinolone acetonide vs intravitreal bevacizumab in diffuse diabetic macular edema. IOSR J Dent Med Sci: IOSR-JDMS 13(6 Ver. IV):01–06

    Google Scholar 

  11. Caldwell RB, Bartoli M, Behzadian MA et al (2003) Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 19:442–455

    Article  CAS  PubMed  Google Scholar 

  12. Antcliff RJ, Marshall J (1999) The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14:223–232

    Article  CAS  PubMed  Google Scholar 

  13. Gillies MC, Sutter FK, Simpson JM et al (2006) Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113:1533–1538

    Article  PubMed  Google Scholar 

  14. Kriechbaum K, Prager S, Mylonas G (2014) Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye 28:9–16

    Article  CAS  PubMed  Google Scholar 

  15. Paccola L, Costa RA, Folgosa MS et al (2008) Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 92(1):76–80

    Article  CAS  PubMed  Google Scholar 

  16. Audren F, Lecleire-Collet A, Erginay A et al (2006) Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 142:794–799

    Article  CAS  PubMed  Google Scholar 

  17. Commertial Diabetic Retinopathy Clinical Research N (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193–1203

    Article  Google Scholar 

  18. Faghihi H, Roohipour R, Mohammadi SF et al (2008) Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 18(6):941–948

    Article  CAS  PubMed  Google Scholar 

  19. Soheilian M, Ramezani A, Obudi A et al (2009) Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 116:1142–1150

    Article  PubMed  Google Scholar 

  20. Wykoff CC, Elman MJ, Regillo CD, Ding B, Lu N, Stoilov I (2016) Predictors of diabetic macular edema treatment frequency with ranibizumab during the open-label extension of the RIDE and RISE trials. Ophthalmology 123(8):1716–1721

    Article  PubMed  Google Scholar 

  21. Radwan SH, Soliman AZ, Tokarev J, Zhang L, van Kuijk FJ, Koozekanani DD (2015) Association of disorganization of retinal inner layers with vision after resolution of center-involved diabetic macular edema. JAMA Ophthalmol 133(7):820–825

    Article  PubMed  Google Scholar 

  22. Mitchell P, Bandello F, Schmidt-Erfurth U et al (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118(4):615–625

    Article  PubMed  Google Scholar 

  23. Shimura M, Nakazawa T, Yasuda K et al (2008) Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 145(5):854–861

    Article  CAS  PubMed  Google Scholar 

  24. Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA (2012) Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina 32(2):314–321

    Article  CAS  PubMed  Google Scholar 

  25. Lim JW (2012) Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmoloqica 227(2):100–106. doi:10.1159/000331935

    Article  CAS  Google Scholar 

  26. Synek S, Vesely P (2011) Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Coll Antropol 35(3):841–845

    CAS  PubMed  Google Scholar 

  27. Liu X et al (2014) Intravitreal bevacizumab with or without triamcinolone acetonide for diabetic macular edema: a meta-analysis of randomized controlled trials. Chin Med J 127(19):3471–3476

    PubMed  Google Scholar 

  28. Shoeibi N, Ahmadieh H, Entezari M, Yaseri M (2014) Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long-term results of a clinical trial. J Ophthalmic Vis Res 8(2):99–106

    Google Scholar 

  29. Diabetic Retinopathy Clinical Research N, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK et al (2007) A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114(10):1860–1867

  30. Browning DJ, Glassman AR, Aiello LP et al (2007) Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 114(3):525–536

    Article  PubMed  Google Scholar 

  31. Schmid KE, Neumaier-Ammerer B, Stolba U, Binder S (2006) Effect of grid laser photocoagulation in diffuse diabetic macular edema in correlation to glycosylated haemoglobin (HbA1c). Graefes Arch Clin Exp Ophthalmol 244:1446–1452

    Article  CAS  PubMed  Google Scholar 

  32. Jonas JB, Martus P, Degenring RF et al (2005) Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema. Arch Ophthalmol 123(10):1338–1343

    Article  CAS  PubMed  Google Scholar 

  33. Diabetic Retinopathy Clinical Research N (2008) A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115(9):1447–449, 9e1–9e10

  34. Cunha-Vaz J, Ashton P, Iezzi R et al (2014) Sustained delivery fluocinolone acetonide vitreous implants. Ophthalmology 121:1892–1903

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Science, Qazvin Square, South Karegar Street, Tehran, 1336616351, Iran

    Mohammad Riazi-Esfahani, Hamid Riazi-Esfahani, Aliasghar Ahmadraji, Reza Karkhaneh, Alireza Mahmoudi, Ramak Roohipoor, Fariba Ghasemi & Mehdi Yaseri

Authors
  1. Mohammad Riazi-Esfahani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hamid Riazi-Esfahani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aliasghar Ahmadraji
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Reza Karkhaneh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alireza Mahmoudi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ramak Roohipoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fariba Ghasemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mehdi Yaseri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Riazi-Esfahani.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Riazi-Esfahani, M., Riazi-Esfahani, H., Ahmadraji, A. et al. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. Int Ophthalmol 38, 585–598 (2018). https://doi.org/10.1007/s10792-017-0496-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-017-0496-4

Keywords

Search

Navigation